Further evidence shows that genetic ablation of TRPV4 suppresses abnormal fibroblast activation after myocardial infarction via the above mechanisms, thereby mitigating adverse cardiac remodeling [7]. This evidence concerns the gene TRPV4 and myocardial infarction.